Phio Pharmaceuticals Corp (PHIO)

[tomsylver]

RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference ( http://investors.rxipharma.com/file.aspx?IID=4418218&FID=25327632 )

Company Release - 09/18/2014 07:02

MARLBOROUGH, Mass., Sept. 18, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the 7th Annual BioPharm America™ Conference on Wednesday, September 24, 2014 at 11:20 a.m. EDT. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's broad delivery technology platform.

The presentation will be available on the "Investors" section of the Company's website, www.rxipharma.com ( http://www.rxipharma.com/ ) .

The seventh annual BioPharm America ( http://www.ebdgroup.com/bpa/index.php ) international life science partnering conference will be held September 22–24 at the Boston Marriott Copley Place in the center of Boston's historic Back Bay. This major industry event is a big draw for pharma and investors who want to access innovative new potential therapies and cures brought by international biotech companies.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI-109, a self-delivering RNAi compound (sd-rxRNA®), entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce the formation of dermal scars (fibrosis). RXI-109 is designed to reduce the expression of connective tissue growth factor (CTGF), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. RXi's sd-rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies. This allows sd-rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity. For more information, please visit www.rxipharma.com ( http://www.rxipharma.com/ ) .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks and uncertainties: the risk that we may not be able to successfully develop our candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based products; risks that the development process for our product candidates may be delayed, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
[e-mail]

SOURCE RXi Pharmaceuticals Corporation